Is MacroGenics, Inc. (MGNX) a Buy, Sell, or Hold?
NASDAQ : MGNX
MacroGenics, Inc.
$3.9 USD
$0.08 (2.09%)
- Volume
- 848.56K
- Average Volume
- 1.2M
- Market Capitalization
- $247.9M
- P/E Ratio
- -3.55
- Dividend Yield
- 0.00%
- Price Target
- $6.00
- Year High
- $5.08
- Year Low
- $1.29
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.90
Company Overview
NASDAQ
Eric Risser
Biotechnology
Healthcare
MGNX
293
US
USD
Liquidity Metrics
1.72
1.90
1.80
0.69
0.00
Sales & Valuation
$149.5M
1.58
11.67
-3.46
-1.13
Profitability
-$1.18
-$74.62M
-44.79%
-45.22%
-147.80%
-32.29%
P/E Metrics
-3.55
0.03
0.03
Analyst Price Target & Rating
$6.00
$6.00
$6.00
1/5
22 Analysts
-35.00%
Financial Health Scores
-7.19
3/9
$86.58M
$217.87M
$196.68M
-$57.72M
Key Metrics (TTM)
$212.8M
1.35
-4.20
1.90
-147.80%
-49.59%
-29.03%
-29.53%
64 days
Company Executives
| Name | Title |
|---|---|
| Araba Lamouse-Smith | Vice President of Technical Operations |
| Beth Smith | Vice President, Controller & Treasurer |
| Ezio Bonvini | Senior Vice President of Research & Chief Scientific Officer |
| Thomas Spitznagel | Senior Vice President of Technical Operations |
| Harish Krishnaswamy | Senior Vice President of Business Development & Portfolio Planning |
| Jeffrey Stuart Peters | Senior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer |
| Frank George Perabo FEBU | Vice President & Interim Head of Clinical Development |
| Eric Blasius Risser | Chief Executive Officer, President & Director |
| Steve Harig | Senior Vice President of Human Resources |
| James Karrels | Senior VP & CFO |
Poll Results
No votes yet today — be the first to share your view!
About MacroGenics, Inc. (NASDAQ:MGNX) Stock
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumor ... s, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of “Hold” by Brokerages
2026-08-03 04:16:08
Shares of MacroGenics, Inc. (NASDAQ: MGNX - Get Free Report) have been given an average rating of "Hold" by the seven ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have issued a buy recommendation on the
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important
2026-07-27 10:35:18
MacroGenics is affirmed as a 'Buy' due to a de-risked operational runway and promising B7-H3 ADC pipeline asset. MGNX's pipeline is refocused after setbacks; cash infusions and divestitures extend the runway through 2028, trading near liquid value. MGC026, the B7-H3 ADC, shows no major safety issues and will present data in late 2026, offering potential upside if efficacy emerges.
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
2026-07-23 16:01:00
Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026 Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling Stage 2 per Simon's two-stage design Ongoing enrollment in other tumor-specific cohorts, including endometrial cancer, melanoma and soft tissue sarcoma ROCKVILLE, MD, July 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug conjugate (ADC), incorporating a topoisomerase I inhibitor-based linker-payload, in patients with advanced solid tumors. MacroGenics plans to present dose escalation and preliminary tumor-specific cohort results at the European Society for Medical Oncology (ESMO) 2026 Congress, taking place October 23-27, 2026, in Madrid, Spain.
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?
2026-07-02 13:01:09
Does MacroGenics (MGNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
2026-07-02 09:25:00
ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, today announced completion of the sale of MacroGenics' good manufacturing practice (GMP) drug substance manufacturing operations to Bora.
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
2026-06-22 16:43:00
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the U.S. Food and Drug Administration's (FDA) accelerated approval of TZIELD® (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 type 1 diabetes (T1D). The approval expands the therapeutic potential of TZIELD as a disease-modifying therapy for type 1 diabetes.
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
2026-05-14 16:01:00
ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum on Wednesday, May 20, 2026 at 10:30 a.m. ET.
MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates
2026-05-13 18:36:10
MacroGenics (MGNX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.65 per share a year ago.
Frequently Asked Questions
-
What is the current MacroGenics, Inc. (MGNX) stock price?
-
MacroGenics, Inc.(NASDAQ:MGNX) stock price is $3.9 in the last trading session. During the trading session, MGNX stock reached the peak price of $5.08 while $1.29 was the lowest point it dropped to. The percentage change in MGNX stock occurred in the recent session was 2.09% while the dollar amount for the price change in MGNX stock was $0.08.
-
MGNX's industry and sector of operation?
-
The NASDAQ listed MGNX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MGNX?
-
Araba Lamouse-Smith | Vice President of Technical Operations
Beth Smith | Vice President, Controller & Treasurer
Ezio Bonvini | Senior Vice President of Research & Chief Scientific Officer
Thomas Spitznagel | Senior Vice President of Technical Operations
Harish Krishnaswamy | Senior Vice President of Business Development & Portfolio Planning -
How many employees does MGNX have?
-
Number of MGNX employees currently stands at 293. MGNX operates from 9704 Medical Center Drive, Rockville, MD 20850, US.
-
Link for MGNX official website?
-
Official Website of MGNX is: http://www.macrogenics.com
-
How do I contact MGNX?
-
MGNX could be contacted at phone #301 251 5172 and can also be accessed through its website. MGNX operates from 9704 Medical Center Drive, Rockville, MD 20850, US.
-
How many shares of MGNX are traded daily?
-
The average number of MGNX shares traded daily for last 3 months was 1.2M.
-
What is the market cap of MGNX currently?
-
The market value of MGNX currently stands at $247.9M with its latest stock price at $3.9